[1] Maruyama H, Okugawa H, Takahashi M, et a1. De novo portal vein thrombosis in virus related cirrhosis: predictive factors and long-term outcomes. Am J Gastroenterol, 2013, 108:568-574.
[2] Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med, 2011, 365:147-165.
[3] Tripodi A,Anstee QM,Sogaard KK, et al. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost, 2011, 9:1713-1723.
[4] Zocco MA, Di Stasio E, De Cristofaro R, et.al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol, 2009, 51:682-689.
[5] 朱辉超, 廖立安, 李胜凯. D-二聚体和白细胞计数在急性肠系膜血管闭塞中的应用价值.现代诊断与治疗, 2016, 27:1330-1331.
[6] Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol, 2012, 10:776-783.
[7] 陆申新, 陈世耀. 抗凝治疗肝硬化患者并发门静脉血栓的循证医学证据. 实用肝脏病杂志, 2016, 19: 624-628. |
